September 25, 2024 11:33 AM EDT

Novo's semaglutide shows potential in chronic skin condition in obese patients

Katherine Lewin

News Reporter

A small study conducted by researchers at St. Vincent’s University Hospital in Dublin suggests that Novo Nordisk’s GLP-1 semaglutide could treat a common and chronic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo's semaglutide shows potential in chronic skin condition in obese patients

Katherine Lewin

News Reporter

Sign up to read this article for free.

Amgen reports dual Phase 3 wins in atopic dermatitis and myasthenia gravis

2seventy bio, Bristol Myers stop late-stage Abecma study in multiple myeloma due to recruitment challenges

Celldex reveals Phase 2 responses for chronic hives drug and higher rates of neutropenia

FDA adcomm will reexamine approval of checkpoint inhibitors in two cancers based on key biomarker

Merck's LAG-3 plus Keytruda combo fails Phase 3 in colorectal cancer

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Novo's semaglu­tide shows po­ten­tial in chron­ic skin con­di­tion in obese pa­tients

Katherine Lewin

News Reporter

Sign up to read this article for free.

Am­gen re­ports dual Phase 3 wins in atopic der­mati­tis and myas­the­nia gravis

2sev­en­ty bio, Bris­tol My­ers stop late-stage Abec­ma study in mul­ti­ple myelo­ma due to re­cruit­ment chal­lenges

Celldex re­veals Phase 2 re­spons­es for chron­ic hives drug and high­er rates of neu­trope­nia

FDA ad­comm will re­ex­am­ine ap­proval of check­point in­hibitors in two can­cers based on key bio­mark­er

Mer­ck­'s LAG-3 plus Keytru­da com­bo fails Phase 3 in col­orec­tal can­cer

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

Novo's semaglutide shows potential in chronic skin condition in obese patients

Amgen reports dual Phase 3 wins in atopic dermatitis and myasthenia gravis

2seventy bio, Bristol Myers stop late-stage Abecma study in multiple myeloma due to recruitment challenges

Celldex reveals Phase 2 responses for chronic hives drug and higher rates of neutropenia

FDA adcomm will reexamine approval of checkpoint inhibitors in two cancers based on key biomarker

Merck's LAG-3 plus Keytruda combo fails Phase 3 in colorectal cancer

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships